EuroMRD NHL 2025 (incl. optional dPCR)

EuroMRD NHL EQA scheme 2025

Task 1: IG/TR-based RQ-PCR

Within this task, quality assessment for IG/TR based minimal residual disease (MRD) RQ-PCR for non-Hodgkin lymphoma (NHL) is performed: Task 1 deals with correct interpretation of IG/TR-RQ-PCR based on real-time quantitative PCR data of 10 patient cases presented as electronic files.

Task 4: IGH::BLC2, IGH::CCND1 and IGH

Task 4 addresses RQ-PCR based MRD assessment in lymphoma.

Task 4A is focused on IGH::BLC2 translocations in follicular lymphoma. Task 4B is focused on IGH::CCND1 and IGH rearrangements in mantle cell lymphoma. Task 4A (spring) and 4B (autumn) are each performed once a year.

Task 4A: IGH::BLC2 RQ-PCR in Follicular Lymphoma: Task 4A consists of MRD RQ-PCR based quantification of IGH::BLC2 major or minor (MBR or mcr) breakpoints on provided samples, according to the instructions provided by the organizers and the EuroMRD guidelines.

Task 4B: IGH::CCND1 and IGH RQ-PCR in Mantle Cell Lymphoma: Task 4B consists of the analysis of two provided sequences, an IGH gene rearrangement and an IGH::CCND1 translocation. For both targets, primers/probe combination must be designed and RQ-PCR analysis performed on FU samples, according to the instructions provided by the organizers and the EuroMRD guidelines.

Optional: Task 8: dPCR for MRD quantification in NHL

Currently Task 8A (IGH::BLC2 dPCR) in Follicular Lymphoma, Task 8B (IGH::CCND1 dPCR) and Task 8C (IGH dPCR) in Mantle Cell Lymphoma are under development.

These tasks consist of the MRD quantification by dPCR on the same targets and FU samples provided for Task 4A and 4B. dPCR analysis should be performed according to the instructions provided by the organizers.

Please indicate whether or not you join the dPCR part/Task 7 in the "Note for ESLHO" field during registration (after you select your schemes and click "Finish registration"). This is important because you will receive a separate set of samples for the dPCR task. Thank you!

Performance evaluation and report

Certificates of participation and performance in EQA rounds will be distributed after the EuroMRD meeting of the same calendar year. Performance criteria of the NHL scheme: a certificate will be provided if at least 75% of points have been received (Task 1+4A, and/or Task 1+4B, respectively), otherwise only a certificate of attendance will be provided for the respective tasks.

EQA Educational meeting

During the ESLHO week in November, the annual EuroMRD meeting is organized. At this meeting, the results of all EuroMRD EQA schemes are shown (anonymized) and discussed with all EuroMRD participants, in small discussion groups as well as during plenary sessions.

Registration and participation fee

The EuroMRD NHL EQA scheme is only available for participants of the EuroMRD Consortium that are part of the NHL section. The participation fee is € 250. In addition, the EuroMRD annual fee is charged once to every EuroMRD participant.

Organization

The NHL EQA scheme is organized by ESLHO (EQA Program Coordinator: Prof. Dr. Jacques J.M. van Dongen) in collaboration with the EuroMRD EQA Committee (NHL scheme lead: Dr. Daniela Drandi). The members of the EuroMRD EQA Committee are participants of the EuroMRD Consortium. The EuroMRD subject-matter experts provide support for:

• Pre-round: Case selection, determination of consensus results

• Post-round: Data analysis, performance evaluation, reporting

Details on the task division can be found below.

Task division